The Team is led by Dr. Philip Low, Founder, Chairman, and CEO of NeuroVigil. 

Dr. Philip Low Founder, Chairman & CEO, NeuroVigil, Inc.

Founder, Chairman, and CEO of NeuroVigil
Research Affiliate, MIT Media Lab
KAVLI Brain and Mind Innovative Research award
Winner, Draper Fisher Jurvetson Venture Challenge
Winner, UCSD Entrepreneurship Challenge
Winner, CONNECT Most Innovative New Product in the Life Sciences
Winner, MIT Technology Review, MIT-TR35 Top Young Innovator under 35
Winner, Fast Company's Top 10 Most Innovative Companies in Health Care
Winner, Jacobs-Rady Pioneer Award for Global Innovation and Entrepreneurship
Winner, New York Times Magazine's 32 Innovations that Will Change Your Tomorrow
The Scientist Magazine's Scientist to Watch

Dr. Low made his first scientific discovery at Harvard Medical School, as a teenager. While inventing new brain monitoring techniques at the University of Chicago, he was referred to the Salk Institute by Francis Crick, Nobel Laureate of DNA fame, where he authored a 1 page PhD thesis on dynamic brain activity mapping, which led to his creation of NeuroVigil, the neurotechnology company responsible for iBrain, a portable brain activity monitor, with first and second round valuations two and two-and-a-half times Google’s and Facebook’s combined, respectively, as well as to the Cambridge Declaration on Consciousness, the first formal document by Neuroscientists recognizing consciousness in non-humans. 

He was appointed to dual positions at the Stanford School of Medicine and the MIT Media Lab in his twenties. His research collaborators include some of the World’s Top Pharma companies and Stephen Hawking, his advisors include Stephen Wolfram and Nobel Laureates Sydney Brenner and Roger Guillemin and his backers include IdeaLab’s Howard Morgan, Qualcomm’s Irwin Jacobs & Andrew Viterbi, DFJ’s Tim Draper and SpaceX’s and Tesla’s Elon Musk. He chaired the 1st Intl. Congress on Alzheimer’s & Advanced Neurotech as well as the Francis Crick Memorial Conference. He advises the White House, Congress, the US Armed Forces and the Israeli Government on Neurotech.

Dr. Low’s honors include the MIT TR-35 Top Young Innovator Award, the DFJ Venture Challenge and the Jacobs-Rady Pioneer Award for Global Innovation & Entrepreneurship. His inventions and discoveries have been profiled in scientific and popular media including Science, PNAS, CNN, TIME, Newsweek, Forbes, the Economist, the Washington Post which lists NeuroVigil as one of the “Top 10 Most Innovative Companies in Health Care”, The Scientist which singled out Dr. Low as “A Scientist to Watch” and the New York Times which has recognized iBrain as “an innovation that will change your tomorrow.”

Legal Counsel
Ian Feinberg Litigation

Mr. Ian Feinberg has over 30 years of extensive experience in handling trials, binding arbitrations, and trial preparation of, and counseling (including litigation avoidance) regarding patent, copyright, trade secret, trademark, licensing, unfair competition, and antitrust matters, particularly in the software and semiconductor industries. He obtained his J.D. at Stanford Law School in 1979, where he made Law Review. He graduated Phi Beta Kappa from Stanford with a B.A. in Economics, with distinction in 1976. He was admitted to the California Bar in 1979 and served on the United States District Courts for Northern, Southern, Central and Eastern Districts of California, the United States District Court of Arizona and United States Court of Appeals for the Ninth Circuit. Ian is one of six NeuroVigil outside counsels. Ian has assisted NeuroVigil in successful licensing transactions and contracts with the Salk Institute and Hoffman - La Roche. Source: Feinberg Day Alberti & Thompson LLP

Richard Ben-Veniste LitigationMr. Richard Ben-Veniste first achieved national prominence during the mid-1970s, when he served as one of the lead prosecutors on the Watergate Special Prosecution Force. He has been a key figure in some of the nation's most significant governmental activities at the intersection of law and politics. From 1995 to 1996, for example, he acted as Chief Counsel (Minority) of the Senate Whitewater Committee; from 1976 to 1977, he was Special Outside Counsel for the Senate Subcommittee on Governmental Operations; and from 1973 to 1975, he held the position of Chief of the Watergate Special Prosecutor's Watergate Task Force. From 2003 to 2004, Richard served as one of ten commissioners on the bipartisan 9-11 Commission. Most recently, in 2009 he served on a task force created by the Secretary of the Department of Homeland Security to assess the national alert system and make recommendations for improvement. Prior to joining Mayer Brown in 2002, Richard was a partner at Weil Gotshal & Manges LLP and Ben-Veniste and Shernoff. From 1968 to 1973 he served as Assistant US Attorney for the Southern District of New York where he was Chief of the Special Prosecutions Section. Richard has been listed in Who's Who in America since 1975, The Best Lawyers in America since 1983, and Washingtonian Magazine's Top Lawyers in Washington, DC since 1992, when the list first appeared. Richard holds a JD from Columbia University Law School where he was a Harlan Fiske Stone Scholar, an LLM from Northwestern University, and an honorary LLD as well as a B.A., Magna Cum Laude, from Muhlenberg College. Source: Mayer Brown, LLP

Jeffrey N. Gibbs FDA Attorney

Mr. Jeffrey N. Gibbs has represented health care companies on FDA-related matters since 1984. He advises companies on a wide variety of issues, including product approvals, marketing, clinical studies, and enforcement. Previously, he served in the Chief Counsel's Office of the U.S. Food and Drug Administration, where he became an Associate Chief Counsel for Enforcement. While at FDA, Mr. Gibbs received the FDA Award of Merit. He also was appointed a Special Assistant United States Attorney for the District of Columbia. Before joining FDA, he clerked for a United States District Court Judge in the District of New Jersey. Mr. Gibbs has written and lectured extensively on a variety of FDA-related topics. Mr. Gibbs served as a member of the Editorial Advisory Board for the Food and Drug Law Journal from 1998 to 2004, and was Chair in 2003-2004. He is currently on the editorial advisory board of IVD Technology and Guide to Good Clinical Practices, and is a member of the Human Subjects Research Board for George Mason University. Mr. Gibbs serves as Secretary and General Counsel of the Board of Directors of the Food and Drug Law Institute. He is a graduate of Princeton University (1975 summa cum laude) and the New York University School of Law (1978 with honors). He is admitted to practice law in the District of Columbia. Source: Hyman, Phelps & McNamara, LLP 

NeuroVigil has several other experienced attorneys on staff for Corporate and IP matters not disclosed here.